GeneDx

OPKO Health Reports Fourth Quarter 2023 Business Highlights and Financial Results

Retrieved on: 
Tuesday, February 27, 2024

MIAMI, Feb. 27, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and 12 months ended December 31, 2023.

Key Points: 
  • MIAMI, Feb. 27, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and 12 months ended December 31, 2023.
    Business highlights from the fourth quarter and subsequent weeks included the following:
    ModeX advanced its antiviral and immune-oncology product pipeline.
  • Operating loss was $16.0 million in the fourth quarter of 2023 compared with $22.0 million in the fourth quarter of 2022.
  • Total costs and expenses for the fourth quarter of 2023 were $166.4 million compared with $162.5 million in the fourth quarter of 2022.
  • Operating loss for the fourth quarter of 2023 was $69.1 million compared with an operating loss of $55.3 million for the 2022 quarter.

GeneDx to Participate in 44th Annual Cowen Health Care Conference

Retrieved on: 
Monday, February 26, 2024

STAMFORD, Conn., Feb. 26, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced that company management will participate in the Cowen Healthcare Conference from March 4-6 in Boston, MA.

Key Points: 
  • STAMFORD, Conn., Feb. 26, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced that company management will participate in the Cowen Healthcare Conference from March 4-6 in Boston, MA.
  • Management will participate in a fireside chat on Wednesday, March 6, 2024, at 10:30 a.m.
  • ET.
  • A live and archived webcast of the presentation will be available on the “Events” section of the GeneDx investor relations website at ir.genedx.com/news-events/events.

GeneDx to Report Fourth Quarter 2023 Financial Results on Tuesday, February 20, 2024 

Retrieved on: 
Thursday, February 1, 2024

STAMFORD, Conn., Feb. 01, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced it will release financial results for the fourth quarter of 2023 after the market closes on Tuesday, February 20, 2024.

Key Points: 
  • STAMFORD, Conn., Feb. 01, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced it will release financial results for the fourth quarter of 2023 after the market closes on Tuesday, February 20, 2024.
  • Management will host a conference call that day to discuss 2023 financial and operating results and share full year 2024 guidance at 4:30 p.m. Eastern Time.
  • Investors interested in listening to the conference call are required to register online.
  • A live and archived webcast of the event will be available on the “Events” section of the GeneDx investor relations website at https://ir.genedx.com/ .

GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Wednesday, January 24, 2024

The RSUs were granted under GeneDx’s 2023 Equity Inducement Plan and in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Points: 
  • The RSUs were granted under GeneDx’s 2023 Equity Inducement Plan and in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The inducement RSUs will vest in equal annual installments over the four-year period following the grant date, subject to the employee’s continued service with the Company on each applicable vesting date.
  • Each RSU represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement.
  • Typically, upon full vesting, shares are sold to cover tax withholding obligations in connection with the vesting and settlement of RSUs and funded by a "sell to cover" transaction.

GeneDx Announces Preliminary 2023 Financial Results

Retrieved on: 
Monday, January 8, 2024

STAMFORD, Conn., Jan. 08, 2024 (GLOBE NEWSWIRE) -- GeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today reported preliminary financial results for the fourth quarter and full year of 2023.

Key Points: 
  • STAMFORD, Conn., Jan. 08, 2024 (GLOBE NEWSWIRE) -- GeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today reported preliminary financial results for the fourth quarter and full year of 2023.
  • The preliminary, unaudited results presented in this press release for the year ended December 31, 2023, are based on current expectations and are subject to adjustment, as the company completes the preparation of its 2023 year-end consolidated financial statements and its 2023 year-end audit.
  • GeneDx will release financial results for the fourth quarter and full year of 2023 after the market closes on Tuesday, February 20, 2024.
  • On the same day, Katherine Stueland, President and Chief Executive Officer of GeneDx, and Kevin Feeley, Chief Financial Officer of GeneDx, will host a conference call to discuss financial and operating results at 4:30 p.m. Eastern Time.

GeneDx Presents New Data at the American Epilepsy Society Annual Meeting Demonstrating That Exome Sequencing Outperforms Multi-Gene Panels for Patients with Epilepsy

Retrieved on: 
Friday, December 1, 2023

The gap in diagnosis between exome sequencing and the multi-gene epilepsy panels can be largely attributed to the fact that more than half (57%) of seizure-related genes are not included on many commercially available epilepsy panels.

Key Points: 
  • The gap in diagnosis between exome sequencing and the multi-gene epilepsy panels can be largely attributed to the fact that more than half (57%) of seizure-related genes are not included on many commercially available epilepsy panels.
  • Of those patients with a positive genetic diagnosis from exome sequencing, 11% had a variant in a treatment related gene.
  • GeneDx will also present data at the conference that shows insurance may offer better coverage for exome sequencing than multi-gene panels for patients with epilepsy.
  • At the conference, GeneDx will also be hosting an industry sponsored symposium discussing the ways in which exome sequencing can help epilepsy patients find answers sooner.

GeneDx to Participate in 6th Annual Evercore ISI HealthCONx Conference

Retrieved on: 
Tuesday, November 28, 2023

STAMFORD, Conn., Nov. 28, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced that company management will participate in the Evercore ISI HealthCONx Conference this week in Miami, FL.

Key Points: 
  • STAMFORD, Conn., Nov. 28, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced that company management will participate in the Evercore ISI HealthCONx Conference this week in Miami, FL.
  • Katherine Stueland, President and Chief Executive Officer, will participate in a fireside chat on Thursday, November 30, 2023, at 10:50 a.m.
  • ET.
  • A live and archived webcast of the presentation will be available on the “Events” section of the GeneDx investor relations website at ir.genedx.com/news-events/events.

GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Monday, November 20, 2023

The RSUs were granted under GeneDx’s 2023 Equity Inducement Plan and in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Points: 
  • The RSUs were granted under GeneDx’s 2023 Equity Inducement Plan and in accordance with Nasdaq Listing Rule 5635(c)(4).
  • Each RSU represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement.
  • Typically, upon full vesting, shares are sold to cover tax withholding obligations in connection with the vesting and settlement of RSUs and funded by a "sell to cover" transaction.
  • This does not represent a discretionary transaction by the Reporting Person.

Madryn Asset Management Highlights Newly-Disclosed Conflicts of Interest Related to Proposed SomaLogic Merger with Standard BioTools

Retrieved on: 
Friday, December 22, 2023

Madryn Asset Management, LP (“Madryn Asset Management” and, collectively with its affiliates, “Madryn”), a holder of approximately 4.2% of the outstanding common stock of SomaLogic, Inc. (“SomaLogic” or the “Company”) (Nasdaq: SLGC), today commented on the additional disclosures provided late yesterday afternoon by SomaLogic related to its proposed merger (the “Proposed Merger”) with Standard BioTools Inc. (“Standard BioTools”) (Nasdaq: LAB).

Key Points: 
  • Madryn Asset Management, LP (“Madryn Asset Management” and, collectively with its affiliates, “Madryn”), a holder of approximately 4.2% of the outstanding common stock of SomaLogic, Inc. (“SomaLogic” or the “Company”) (Nasdaq: SLGC), today commented on the additional disclosures provided late yesterday afternoon by SomaLogic related to its proposed merger (the “Proposed Merger”) with Standard BioTools Inc. (“Standard BioTools”) (Nasdaq: LAB).
  • Madryn issued the following statement:
    SomaLogic’s additional disclosures—which were only made after the Company had been sued by two separate shareholders—provide significant reasons for shareholders to be skeptical of the Proposed Merger.
  • The fact that these disclosures were made only two weeks ahead of the planned vote compounds the ongoing governance failures present at the Company.
  • We continue to urge SomaLogic shareholders to vote “AGAINST” the Proposed Merger.

Anagenex Strengthens Board of Directors with Appointments of Robert Forrester and Isaac Ro

Retrieved on: 
Thursday, November 16, 2023

The company also welcomed Isaac Ro to its Board of Directors.

Key Points: 
  • The company also welcomed Isaac Ro to its Board of Directors.
  • “Robert and Isaac’s extensive experience as life science executives is invaluable to the Anagenex team as we realize our vision of becoming a vertically integrated small molecule drug discovery company,” said Nicolas Tilmans, CEO of Anagenex.
  • “Our unique AI driven platform has already powered two lead programs with novel chemical matter and continues to scale.
  • Isaac Ro has extensive experience as an investor, board member and operator having navigated multiple financings, M&A transactions and exits.